Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of MSC Exosome Ointment in Healthy Volunteers
NCT05523011Phase 1Completed
- Sponsor
- Paracrine Therapeutics
- Start
- Mar 2022
- Primary completion
- Apr 2022
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PTD2021P in psoriasis, sponsored by Paracrine Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events, Incidence Rate of Local Skin Responses (LSR) at Day 21 and 6 more. Started Mar 2022; status: completed.
02
Drugs
PTD2021P
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT05523011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05523011.